The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Causality unclear when the drug is given along with chemo agents. See also: Okafor C, et al. Panitumumab Implicated in another case of interstitial lung disease. Am J Respir Crit Care Med 2019; 199: A6279 (Abstract)

Publications

Arora R, Kisiel M, MacColl C

Panitumumab-induced pulmonary toxicity.

Current oncology (Toronto, Ont.). 2019;26(5):e700-e702

Rezkallah KNM, Ahmed A, Patel S, Kozma K

A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.

BMJ case reports. 2019;12(2)

Al-Asadi O, Almusarhed M, Rizvi SAJ, Saka W

Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen.

Ecancermedicalscience. 2018;12:841